Abbott Laboratories (ABT) FinancialsABTFinancialAbbott Laboratories

Abbott Laboratories (ABT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical Devices, accounting for 49.6% of total sales, equivalent to $5.54B. Other significant revenue streams include Diagnostics Products and Nutritionals Products. Understanding this composition is critical for investors evaluating how ABT navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Abbott Laboratories maintains a gross margin of 52.49%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.44%, while the net margin is 7.37%. These profitability ratios, combined with a Return on Equity (ROE) of 10.67%, provide a clear picture of how effectively ABT converts its operational activities into shareholder value.

In the context of the broader market, ABT competes directly with industry leaders such as TMO and DHR. With a market capitalization of $192.51B, it holds a significant position in the sector. When comparing efficiency, ABT's gross margin of 52.49% stands against TMO's 40.70% and DHR's 57.64%. Such benchmarking helps identify whether Abbott Laboratories is trading at a premium or discount relative to its financial performance.

Abbott has shown solid revenue growth, with total revenue reaching $12.593 billion in Q2 2026, up from $11.164 billion in Q1 2026. The gross margin remains strong at 52.49%, indicating effective cost management and profitability.